Mahmud Zabed, Tikunova Svetlana, Belevych Natalya, Wagg Cory S, Zhabyeyev Pavel, Liu Philip B, Rasicci David V, Yengo Christopher M, Oudit Gavin Y, Lopaschuk Gary D, Reiser Peter J, Davis Jonathan P, Hwang Peter M
Department of Biochemistry, University of Alberta, Edmonton, AB, Canada.
Department of Physiology and Cell Biology, The Ohio State University, Columbus, OH, United States.
Front Physiol. 2022 Jun 8;13:892979. doi: 10.3389/fphys.2022.892979. eCollection 2022.
Small molecule cardiac troponin activators could potentially enhance cardiac muscle contraction in the treatment of systolic heart failure. We designed a small molecule, RPI-194, to bind cardiac/slow skeletal muscle troponin (Cardiac muscle and slow skeletal muscle share a common isoform of the troponin C subunit.) Using solution NMR and stopped flow fluorescence spectroscopy, we determined that RPI-194 binds to cardiac troponin with a dissociation constant K of 6-24 μM, stabilizing the activated complex between troponin C and the switch region of troponin I. The interaction between RPI-194 and troponin C is weak (K 311 μM) in the absence of the switch region. RPI-194 acts as a calcium sensitizer, shifting the pCa of isometric contraction from 6.28 to 6.99 in mouse slow skeletal muscle fibers and from 5.68 to 5.96 in skinned cardiac trabeculae at 100 μM concentration. There is also some cross-reactivity with fast skeletal muscle fibers (pCa increases from 6.27 to 6.52). In the slack test performed on the same skinned skeletal muscle fibers, RPI-194 slowed the velocity of unloaded shortening at saturating calcium concentrations, suggesting that it slows the rate of actin-myosin cross-bridge cycling under these conditions. However, RPI-194 had no effect on the ATPase activity of purified actin-myosin. In isolated unloaded mouse cardiomyocytes, RPI-194 markedly decreased the velocity and amplitude of contractions. In contrast, cardiac function was preserved in mouse isolated perfused working hearts. In summary, the novel troponin activator RPI-194 acts as a calcium sensitizer in all striated muscle types. Surprisingly, it also slows the velocity of unloaded contraction, but the cause and significance of this is uncertain at this time. RPI-194 represents a new class of non-specific troponin activator that could potentially be used either to enhance cardiac muscle contractility in the setting of systolic heart failure or to enhance skeletal muscle contraction in neuromuscular disorders.
小分子心肌肌钙蛋白激活剂在治疗收缩性心力衰竭方面可能会增强心肌收缩力。我们设计了一种小分子RPI - 194,使其与心肌/慢肌骨骼肌肌钙蛋白结合(心肌和慢肌骨骼肌共享肌钙蛋白C亚基的一种共同异构体)。通过溶液核磁共振和停流荧光光谱法,我们确定RPI - 194与心肌肌钙蛋白结合的解离常数K为6 - 24μM,稳定了肌钙蛋白C与肌钙蛋白I开关区域之间的活化复合物。在没有开关区域的情况下,RPI - 194与肌钙蛋白C的相互作用较弱(K为311μM)。RPI - 194作为一种钙敏化剂,在100μM浓度下,使小鼠慢肌骨骼肌纤维等长收缩的pCa从6.28变为6.99,使去表皮心肌小梁的pCa从5.68变为5.96。它与快肌骨骼肌纤维也有一些交叉反应(pCa从6.27增加到6.52)。在对相同去表皮骨骼肌纤维进行的松弛试验中,RPI - 194在钙浓度饱和时减缓了无负荷缩短的速度,这表明在这些条件下它减缓了肌动蛋白 - 肌球蛋白横桥循环的速率。然而,RPI - 194对纯化的肌动蛋白 - 肌球蛋白的ATP酶活性没有影响。在分离的无负荷小鼠心肌细胞中,RPI - 194显著降低了收缩的速度和幅度。相比之下,在小鼠离体灌注工作心脏中,心脏功能得以保留。总之,新型肌钙蛋白激活剂RPI - 194在所有横纹肌类型中都作为钙敏化剂起作用。令人惊讶的是,它还减缓了无负荷收缩的速度,但目前其原因和意义尚不确定。RPI - 194代表了一类新型的非特异性肌钙蛋白激活剂,有可能用于在收缩性心力衰竭情况下增强心肌收缩力,或用于增强神经肌肉疾病中的骨骼肌收缩力。